San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Amplyx Pharmaceuticals is raising $102,736,838.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Ciara Kennedy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amplyx Pharmaceuticals

Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s leadership has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare conditions.

To learn more about Amplyx Pharmaceuticals, visit http://www.amplyx.com/

Contact:
Ciara Kennedy, President and Chief Executive Officer
858-345-1755
ckennedy@amplyx.com
https://www.linkedin.com/in/ciara-kennedy-995b98/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved